Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Published June 2026 | Last reviewed June 2026
Key Takeaways
- Reported ATTR-CM prevalence and incidence are shaped by recognition, testing access, and diagnostic pathways—not by disease biology alone.
- The rise in cases may reflect greater awareness and more structured workups rather than a confirmed true increase in disease.
- Reported differences in ATTR-CM by sex and geographic region reflect both underlying disease biology and ascertainment, age structure, ancestry, and genotype distribution.
Why Recognition Shapes ATTR-CM Prevalence and Incidence
Reported ATTR-CM frequency reflects detection as much as underlying biology. Prevalence and incidence estimates depend on whether clinicians suspect the diagnosis, whether they pursue confirmatory testing, and whether the necessary imaging and laboratory workup are available. Where suspicion and access are higher, more disease may be found; where they are lower, the same biology may go undetected. For this reason, epidemiologic figures should be viewed as a lower-bound estimate shaped by ascertainment, rather than a precise measure of true burden. This recognition-dependent pattern also connects directly to the risk factors that influence whether clinicians look for ATTR-CM in the first place.
Sex, Age, and Geography in Reported ATTR-CM
Observed demographic patterns are partly genuine and partly an artifact of how cases are found. Older men are diagnosed more often, but ascertainment bias may contribute to that skew. Additionally, local case counts are shaped by population age structure, ancestry, genotype distribution, and testing access as much as by disease biology. Lastly, hereditary disease clusters in certain ancestral groups, which further shifts where variant ATTR-CM is detected. Reading these differences alongside the broader ATTR-CM overview keeps demographic signals in perspective.
Reading Apparent Rises in ATTR-CM with Caution
An apparent increase in ATTR-CM does not by itself prove the disease is becoming more common. Greater awareness, wider use of bone-avid scintigraphy, and more structured diagnostic pathways can all make the disease look more frequent even without a true biologic change, a pattern explored further in how under-recognition distorts the map. For population-level interpretation, the practical takeaway is simple: trends in detection are not the same as trends in disease. The most reliable way to turn clinical suspicion into a confirmed, counted case remains a disciplined screening and early-detection sequence.
Frequently Asked Questions
Is ATTR-CM rare?
It has historically been considered uncommon, but it’s now recognized as underdiagnosed rather than simply rare. As awareness and noninvasive testing have spread, more cases are being identified, particularly among older adults with otherwise unexplained heart failure and increased wall thickness.
Why is the prevalence of ATTR-CM rising?
Much of the increase is attributed to better recognition, wider availability of bone-avid scintigraphy, and more structured diagnostic pathways. A true biologic increase has not been established, so rising detection should not be conflated with rising disease.
Does ATTR-CM affect men and women differently?
Wild-type ATTR-CM is diagnosed more often in older men, though ascertainment patterns may contribute to the apparent skew and the disease is increasingly recognized in women. Hereditary disease distribution also varies by ancestry and specific transthyretin genotype.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- ATTR Epidemiology, Genetics, and Prognostic Factors. PubMed
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. PubMed
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.